| Domestic Branded Formulations | Branded generics in cardiology, anti-diabetes, pain management, dermatology, and women’s health | Strong sales force, specialist market penetration, proprietary brands, and established physician relationships | Primarily B2B targeting specialist doctors, hospitals, and clinics across India | Anti-diabetes, insulins, dermatology | 2637 | 92 | Direct sales through field force to specialists; prescription-driven revenue | Direct sales model with competitive pricing in chronic specialty therapies | New product launches, therapy area expansion, patient care initiatives, and market share gains | Gluxit, Racelto, Zomelis, Serlift, Desval ER, Sonaxa, Levroxa |
| International Business & Contract Manufacturing | Export of branded generics, injectables, biologic fill-finish, and contract manufacturing services | Globally compliant manufacturing facilities, extensive dossier bank, and long-term supply agreements | Pharma firms across 70+ countries including Latin America, Africa, Asia-Pacific, Middle East and Europe | Sterile injectable manufacturing and biologics fill-finish | 242 | 8 | International sales to distributors, contract manufacturing revenue from CDMO clients | B2B contracts, regulated and tender markets, recurring orders | ANVISA, EU-GMP approvals, expanding CDMO contracts, and dossier pipeline growth | Swiss Parenterals Injectable portfolio, EU-CDMO client products |
